Russia’s AI-backed, tailored mRNA vaccine for cancer moves to human testing phase
Cancer cure is inching closer to reality as Russia’s Gamaleya Research Institute of Epidemiology and Microbiology has announced that personalized treatment could start within months. The landmark drug is an AI-assisted, personalized, mRNA-based vaccine meant to target malignant tumors using the genetic data of a patient.
The Director of the Gamaleya Research Institute of Epidemiology and Microbiology, Alexander Gintsburg, inferred that the experimental phase of administering the vaccine would begin with the cooperation of leading oncology institutions–Blokhin Cancer Center and Hertsen Research Institute, stated RT, citing RIA Novosti. Gintsburg has reportedly stated that patient trials will be conducted by the partnering clinics, while the Gamaleya Center will be committed to producing the vaccine.
He explained that the experimental treatment would witness the use of the cancer vaccine based on neoantigens in a group of melanoma patients. The “entirely personalized” drug will be specific to each patient’s tumor; the vaccine will be subject to a unique regulatory framework.
The cancer vaccine has allegedly shown remarkable results in animal trials and limited tests on human patients. The Director had apparently credited artificial intelligence for helping complete the entire production in a week (from assessing the tumor to creating a tailored vaccine). It corroborates the hegemony of AI in healthcare market, which could provide a USD 187.69 billion revenue opportunity by 2030, estimates Grand View Research.
It is worth noting that the Gamaleya Center, the creator of the Sputnik V COVID-19 vaccine, is developing models for treating kidney, pancreatic, and non-small-cell lung cancer.
For the record, the work on the vaccine development started in the mid-2022. The treatment uses mRNA technology to train the patient’s immune system to target and decimate malignant cells throughout the body (using cytotoxic lymphocytes). The process involves using advanced AI algorithms to analyze the genetic data of the tumor to produce a molecular template.
The Economic Times reports that Russia will provide the cancer vaccine free of charge to its citizens; the government funding would cover the estimated production cost of approximately 300,000 rubles (around USD 2,869) per dose. The Global watchdogs are keeping an eye on the potential paradigm shift observed in the Russia’s health industry.
